Clearmind Medicine Inc. CMND
4.98 USD -0.11 (-2.16%)
Nov 11, 2026, 3:45 PM EST
4.94 Day range 5.58
4.94 52-week range 2,076.80
- YTD
- -96.56%
- 1 year
- -99.66%
News
globenewswire.com Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit Vancouver, Canada, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
benzinga.com Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable…
benzinga.com Clearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platform Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation
benzinga.com Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of…
benzinga.com Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026 learmind Medicine Inc. (the "Company") is announcing that it will effect a reverse share split of the Company’s common shares at the ratio of 1-for-8, such that each eight (8) common shares, no par…
benzinga.com Clearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As Palmitoylethanolamide The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression, post-traumatic stress disorder ("PTSD"), pain and…
benzinga.com Clearmind Medicine Says Yale University’s IRB Approves Initiation Of Patient Recruitment For Parts B And C Of Phase I/II Clinical Trial Evaluating CMND‑100 Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company" or "Clearmind"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies…
benzinga.com Clearmind Medicine Stock Slides Friday: What's Happening? Clearmind Medicine shares are trading lower Friday as investors weigh the biotech’s move to acquire a majority stake in an EV charging firm.- benzinga.com Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of…
- benzinga.com SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on
- benzinga.com Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical company advancing non-hallucinogenic, psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric,…
benzinga.com Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.- benzinga.com Clearmind Medicine Announces Safety Results From Part A Of Its Ongoing FDA-regulated Phase I/II Clinical Trial Evaluating CMND-100; All 24 Participants Enrolled Across Four Ascending-Dose Cohorts Successfully Completed Treatment Completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candidate, CMND-100. The study achieved its primary endpoint of safety and tolerability. CMND-100…
- benzinga.com Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use Disorder All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol.The Company is currently assessing the dataset and, assuming results remain…
- benzinga.com Clearmind Medicine Files Hong Kong Patent Application For Innovative Psychedelic Compounds For Treatment Of Post-Traumatic Stress Disorder The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"). Under the…
benzinga.com Clearmind Medicine Announces Ex Vivo Mucoadhesion Results For Intranasal MEAI; New Formulation Demonstrated Markedly Improved Nasal Residence Characteristics Compared With Standard MEAI Solution Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy of developing differentiated, next‑generation…
benzinga.com Clearmind Medicine Announces CMND‑100, Current Phase I/IIa Trial Demonstrates Impression To Treat Alcohol Use Disorder Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,
benzinga.com Clearmind Medicine Files Response To U.S. Department Of Health And Human Services Request For Information About MEAI's Potential To Treat Addiction Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived therapeutics to solve major under-treated…- benzinga.com Clearmind Medicine Announces Progress In Evaluating Intranasal Delivery Of Its Proprietary MEAI Treatment For Alcohol Use Disorder The program is evaluating intranasal delivery of MEAI as a potential additional route of administration, with initial studies focused on assessing formulation feasibility and supporting the continued…
- benzinga.com Clearmind Medicine Granted Additional US Patent Titled BINGE BEHAVIOR REGULATORS By USPTO Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,
- benzinga.com Clearmind Medicine Completes Treatment For All Participants In Part A Of Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Treatment Of Alcohol Use Disorder Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,
- benzinga.com UPDATE: Clearmind Medicine Secures U.S. Patent Covering MEAI-Based Compositions And Methods For Regulating Binge Drinking, Eating, And Gambling Behaviors Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,…
- benzinga.com Clearmind Medicine Completes Dosing Of All 24 Participants In Groups 1 To 4 Of Part A Of Its Phase I/II Clinical Study Of CMND-100 To Treat Alcohol Use Disorder Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Clearmind Medicine To Host June 10 Webinar On The Latest Clinical Data From Its Phase I/IIa Trial Evaluating CMND-100 Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Taylor Morrison Home Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announced to acquire the homebuilder.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Clearmind Medicine Files Japanese Patent Application For Its Proprietary Compositions Comprising 5-Methoxy-2-Aminoindan To Treat Depression This advancement strengthens Clearmind's robust intellectual property portfolio, which already includes multiple granted patents and applications worldwide. MEAI, the company's flagship…
- benzinga.com Clearmind Medicine Announces Johns Hopkins Approval For CMND-100 Phase 1/2 Clinical Trial The approval advances the multicenter study titled "A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder…
benzinga.com Gold Falls 1%; Amer Sports Earnings Top Views US stocks down, Nasdaq drops 200 points. Dow -0.35% at 49,512.48, Nasdaq -0.93% at 25,849.08, S&P 500 -0.56% at 7,361.93. Health care up 1.2%, materials down 2.1%. Amer Sports beats Q1 earnings,…
benzinga.com Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings US stocks fall, Dow Jones down 0.34% & NASDAQ down 0.41% in morning trading. Home Depot reports upbeat earnings, while materials stocks drop 1.8%.- benzinga.com Clearmind Medicine Inks Research Agreement With Yissum Research Development To Evaluate Metabolic Efficacy Of MEAI Both In Combination With, Maintenance Therapy Following Tirzepatide Treatment In Diet-Induced Obese Mice Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation,…
- benzinga.com Clearmind Medicine Announces Dosing Of Two Additional Patients In Fourth Group Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Moderate To Severe Alcohol Use Disorder Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,…
- benzinga.com Clearmind Medicine Shares New CMND-100 Clinical Trial Data Ahead Of June Investor Webinar Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,…
- benzinga.com Clearmind Medicine Files European Patent Application For Innovative Psychedelic Compounds Targeting The Treatment Of Post-Traumatic Stress Disorder And Other Mental Health Disorders The European patent application forms part of the Company's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"). Under…
- benzinga.com Clearmind Medicine Evaluates Lead Candidate, CMND-100 (MEAI), For Eligibility For FDA's Breakthrough Therapy Designation Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy DesignationVancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE) --…
benzinga.com Why Is Clearmind Medicine Stock Sliding On Wednesday? Clearmind Medicine Inc. (NYSE: CMND) faces a price correction Wednesday following a massive rally. Read more on the impact of CMND-100 trial results and new executive orders.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Dow Gains Over 200 Points; US Retail Sales Top Estimates US stocks up as Dow Jones gains 0.48% and NASDAQ rises 0.03%. Retail sales up 1.7% in March, while private employers add 54,750 jobs per week.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session